Glutarate

Glutarate

SCHEMBL722388

NCC(N)=O.O=C(O)CCCC(=O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 1/20 0.65
LMNA P02545 5/20 0.60
TSHR P16473 3/20 0.60
THRB P10828 2/20 0.60
BLM P54132 2/20 0.60
KMT2A Q03164 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
GABRR1 P24046 2/20 0.60
GABRR3 A8MPY1 1/20 0.60
GABRP O00591 1/20 0.60
GABRD O14764 1/20 0.60
HDAC3 O15379 1/20 0.60
GABBR2 O75899 1/20 0.60
CYP1A2 P05177 1/20 0.60
GABRA1 P14867 1/20 0.60
GABRB1 P18505 1/20 0.60
GABRG2 P18507 1/20 0.60
GABRB3 P28472 1/20 0.60
GABRR2 P28476 1/20 0.60
SLC6A1 P30531 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutarate SCHEMBL28412854 1.00 SLC22A6 (0.65) SLC22A6LMNATSHRTHRBBLM
SCHEMBL436313 0.88
Succinic Acid SCHEMBL468818 0.88 GABRR1 (0.63) SLC22A6LMNATSHRTHRBBLM
Succinic Acid SCHEMBL27999204 0.88 GABRR1 (0.63) SLC22A6LMNATSHRTHRBBLM
Adipic Acid SCHEMBL28391561 0.85 LMNA (0.69) SLC22A6LMNATSHRTHRBBLM
Adipic Acid SCHEMBL28391560 0.85 LMNA (0.69) SLC22A6LMNATSHRTHRBBLM
Glutarate SCHEMBL28950263 0.85 SLC22A6 (0.69) SLC22A6LMNATSHRTHRBBLM
Glutarate SCHEMBL28950262 0.85 SLC22A6 (0.69) SLC22A6LMNATSHRTHRBBLM
Hydrochloric Acid SCHEMBL27449805 0.85 SLC22A6 (0.69) SLC22A6LMNATSHRTHRBBLM
Hydrogen Sulfide SCHEMBL9451706 0.85 SLC22A6 (0.69) SLC22A6LMNATSHRTHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9585988-B2 Anchorage devices comprising an active pharmaceutical ingredient TYRX, INC. (US) 2017-03-07 US claimed
US-12447242-B2 Hemostatic devices and methods of use MEDTRONIC, INC. (US) 2025-10-21 US disclosed
EP-3452124-B1 HEMOSTATIC DEVICES AND METHODS OF USE MEDTRONIC INC (US) 2025-10-08 EP disclosed
EP-3452123-B1 HEMOSTATIC DEVICES AND METHODS OF USE MEDTRONIC INC (US) 2025-09-24 EP disclosed
EP-3452126-B1 HEMOSTATIC DEVICES AND METHODS OF USE MEDTRONIC INC (US) 2025-08-27 EP disclosed
US-20250262358-A1 SURGICAL SYSTEM AND METHODS OF USE MEDTRONIC INC (US) 2025-08-21 US disclosed
EP-3452125-B1 CUSTOMIZABLE ANCHORAGE DEVICES AND METHODS OF USE MEDTRONIC INC (US) 2025-07-16 EP disclosed
US-20250152332-A1 SURGICAL SYSTEM AND METHODS OF USE MEDTRONIC, INC. 2025-05-15 US disclosed
US-12168085-B2 Surgical system and methods of use MEDTRONIC, INC (US) 2024-12-17 US disclosed
US-12168086-B2 Hemostatic devices and methods of use MEDTRONIC, INC (US) 2024-12-17 US disclosed
EP-2079387-A1 MESH POUCHES FOR IMPLANTABLE MEDICAL DEVICES TYRX PHARMA INC. (US) 2009-07-22 EP disclosed
EP-2079389-A2 RESORBABLE POUCHES FOR IMPLANTABLE MEDICAL DEVICES TYRX PHARMA INC. (US) 2009-07-22 EP disclosed
US-20090018559-A1 Temporarily Stiffened Mesh Prostheses TYRX PHARMA, INC. (US) 2009-01-15 US disclosed
WO-2008136856-A2 RESORBABLE POUCHES FOR IMPLANTABLE MEDICAL DEVICES TYRX PHARMA, INC. (US) 2008-11-13 WO disclosed
WO-2008127411-A1 MESH POUCHES FOR IMPLANTABLE MEDICAL DEVICES TYRX PHARMA, INC. (US) 2008-10-23 WO disclosed
WO-2008121816-A2 BIODEGRADABLE, POLYMER COVERINGS FOR BREAST IMPLANTS TYRX PHARMA, INC. (US) 2008-10-09 WO disclosed
US-20080241212-A1 Tyrosine-derived aromatic polyester sheet, film or mat of nanofibers optionally including anesthetics, antiinflammatories, microbiocides, leukotriene inhibitors, or antiscarring, antifibrotic, or antineoplastic agents, and that resists capsular contracture and adherence to the implant TYRX PHARMA, INC. (US) 2008-10-02 US disclosed
US-20080132922-A1 Mesh Pouches for Implantable Medical Devices TYRX PHARMA, INC. (US) 2008-06-05 US disclosed
US-20080128315-A1 Biodegradable polylactic acid polymer pouches for pacemaker, defibrillator, pulse generator cardiac rhythm mamagent devices; antimicrobial agents, anesthetics, anti-inflammatory agents, anti-scarring drugs in polymer matrix; barrier to microbial colonization of medical device during surgical implantation TYRX PHARMA, INC. (US) 2008-06-05 US disclosed
US-20070198040-A1 Temporarily Stiffened Mesh Prostheses TYRX PHARMA INC. (US) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12168086-B2 Hemostatic devices and methods of use PLAT, HABP2, F2 SLC22A6 4736/4885LMNA 638/4885TSHR 3934/4885
US-12168085-B2 Surgical system and methods of use FGB, F2, COL14A1 SLC22A6 4791/4885LMNA 488/4885TSHR 3430/4885
US-12447242-B2 Hemostatic devices and methods of use HABP2, PLAT, F2 SLC22A6 4809/4885LMNA 624/4885TSHR 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.